Soleno Therapeutics Inc (SLNO)

Currency in USD
82.3500
+3.6400(+4.62%)
Closed·
After Hours
82.3600+0.0100(+0.01%)
·
SLNO Scorecard
Full Analysis
Net income is expected to grow this year
SLNO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
77.332382.5700
52 wk Range
41.500090.3199
Key Statistics
Prev. Close
78.71
Open
77.6
Day's Range
77.3323-82.57
52 wk Range
41.5-90.3199
Volume
1.07M
Average Volume (3m)
1.08M
1-Year Change
82.68%
Book Value / Share
4.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLNO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Soleno Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Soleno Therapeutics Inc Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics Inc SWOT Analysis


FDA Milestone
Soleno Therapeutics secures FDA approval for VYKAT XR, a groundbreaking treatment for Prader-Willi Syndrome, positioning the company as a key player in rare disease therapeutics
Market Dynamics
Explore the potential of VYKAT XR in a 10,000-patient market, with a strategic focus on 300 top specialists to drive initial adoption and maximize impact
Financial Outlook
Delve into Soleno's robust financial position, with $285 million in cash reserves and a conservative revenue projection, as analysts set price targets ranging from $67 to $123
Competitive Edge
Uncover Soleno's advantages in the PWS treatment landscape, including unmet medical needs, strong clinical data, and a clean FDA label, potentially accelerating VYKAT XR's market penetration
Read full SWOT analysis

Soleno Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.09 beat forecast of -$0.64; revenue of $32.7M exceeded expectations by 113.03%
  • VICAT XR launch successful; company exploring European market expansion for PWS treatment
  • Pro forma cash balance over $500M; projecting annual cash operating expenses of $120-130M
  • Stock dipped 0.54% post-earnings despite strong results; analyst targets suggest potential upside
  • No new safety signals for VICAT XR; company actively seeking strategic partnerships for European entry
Last Updated: 07/08/2025, 08:36
Read Full Transcript

Compare SLNO to Peers and Sector

Metrics to compare
SLNO
Peers
Sector
Relationship
P/E Ratio
−24.0x−4.0x−0.5x
PEG Ratio
0.200.010.00
Price/Book
18.1x2.5x2.6x
Price / LTM Sales
133.1x150.6x3.3x
Upside (Analyst Target)
49.9%137.4%43.5%
Fair Value Upside
Unlock6.5%6.8%Unlock

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.09 / -0.64
Revenue / Forecast
32.70M / 15.35M
EPS Revisions
Last 90 days

SLNO Income Statement

People Also Watch

91.98
RYTM
-0.54%
247.45
AVAV
-4.68%
105.280
VRNA
-0.11%
27.37
VCYT
-1.12%
17.75
URGN
-4.52%

FAQ

What Stock Exchange Does Soleno Therapeutics Trade On?

Soleno Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Soleno Therapeutics?

The stock symbol for Soleno Therapeutics is "SLNO."

What Is the Soleno Therapeutics Market Cap?

As of today, Soleno Therapeutics market cap is 4.35B.

What Is Soleno Therapeutics's Earnings Per Share (TTM)?

The Soleno Therapeutics EPS (TTM) is -3.97.

When Is the Next Soleno Therapeutics Earnings Date?

Soleno Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is SLNO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Soleno Therapeutics Stock Split?

Soleno Therapeutics has split 2 times.

How Many Employees Does Soleno Therapeutics Have?

Soleno Therapeutics has 92 employees.

What is the current trading status of Soleno Therapeutics (SLNO)?

As of 09 Aug 2025, Soleno Therapeutics (SLNO) is trading at a price of 82.35, with a previous close of 78.71. The stock has fluctuated within a day range of 77.33 to 82.57, while its 52-week range spans from 41.50 to 90.32.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.